{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:59:32Z","timestamp":1785117572209,"version":"3.55.0"},"reference-count":0,"publisher":"AME Publishing Company","content-domain":{"domain":["amegroups.com"],"crossmark-restriction":false},"short-container-title":["Transl Gastroenterol Hepatol"],"DOI":"10.21037\/tgh-2026-0084","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:08:42Z","timestamp":1784689722000},"page":"75-75","update-policy":"https:\/\/doi.org\/10.21037\/ame_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination therapeutics for hepatitis delta virus infection: implications of the tobevibart-elebsiran SOLSTICE phase 2 trial"],"prefix":"10.21037","volume":"11","author":[{"given":"Peter D.","family":"Block","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph K.","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8611","published-online":{"date-parts":[[2026,7]]},"container-title":["Translational Gastroenterology and Hepatology"],"original-title":[],"link":[{"URL":"https:\/\/tgh.amegroups.com\/article\/download\/10614\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T01:25:08Z","timestamp":1785115508000},"score":1,"resource":{"primary":{"URL":"https:\/\/tgh.amegroups.com\/article\/view\/10614\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21037\/tgh-2026-0084","relation":{},"ISSN":["2415-1289"],"issn-type":[{"value":"2415-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}